Section 6 of 6
References
199 sources
- American Psychological Association Mental and Behavioral Health Registry measures page (2026) (opens in a new tab)
- Archer et al. (2012) (opens in a new tab)
- Arikci et al. (2025) (opens in a new tab)
- Baldwin et al. (2014) (opens in a new tab)
- Bandelow (2006) (opens in a new tab)
- Bandelow et al. (2015) (opens in a new tab)
- Bandelow et al. (2023) (opens in a new tab)
- Batelaan et al. (2016) (opens in a new tab)
- Batelaan et al. (2017) (opens in a new tab)
- Becker et al. (2023) (opens in a new tab)
- Becker et al. (2025) (opens in a new tab)
- Bentley et al. (2016) (opens in a new tab)
- Berger et al. (2011) (opens in a new tab)
- BrainFutures CPT and HCPCS coding guide (2023) (opens in a new tab)
- Bruce et al. (2005) (opens in a new tab)
- BuSpar prescribing information (2010) (opens in a new tab)
- Carhart-Harris and Nutt (2017) (opens in a new tab)
- Carl et al. (2020) (opens in a new tab)
- Chessick et al. (2006) (opens in a new tab)
- ClinicalTrials.gov NCT00920387 (opens in a new tab)
- ClinicalTrials.gov NCT00920387 results (opens in a new tab)
- ClinicalTrials.gov NCT03153579 (opens in a new tab)
- ClinicalTrials.gov NCT05407064 (opens in a new tab)
- ClinicalTrials.gov NCT05407064 results (opens in a new tab)
- ClinicalTrials.gov NCT05964647 (opens in a new tab)
- ClinicalTrials.gov NCT06741228 (opens in a new tab)
- ClinicalTrials.gov NCT06809595 (opens in a new tab)
- CMS CY 2020 Physician Fee Schedule final rule (2019) (opens in a new tab)
- CMS Use of High-Risk Medications in Older Adults eCQM flow (2025) (opens in a new tab)
- Costello et al. (2019) (opens in a new tab)
- COVID-19 Mental Disorders Collaborators (2021) (opens in a new tab)
- CTIS 2024-513572-17-00 (opens in a new tab)
- Cubała (2026) (opens in a new tab)
- Cuijpers et al. (2014) (opens in a new tab)
- Cymbalta prescribing information (2023) (opens in a new tab)
- de Vries et al. (2018) (opens in a new tab)
- Definium Therapeutics corporate presentation (2026) (opens in a new tab)
- Definium Therapeutics executive order statement (2026) (opens in a new tab)
- Definium Therapeutics expanded access policy (2025) (opens in a new tab)
- Definium Therapeutics first quarter 2026 results announcement (2026) (opens in a new tab)
- Definium Therapeutics Form 10-K (2026) (opens in a new tab)
- Definium Therapeutics Form 8-K name change (2026) (opens in a new tab)
- Definium Therapeutics full-year 2025 results announcement (2026) (opens in a new tab)
- Definium Therapeutics GAD fact sheet (2026) (opens in a new tab)
- Definium Therapeutics Investor and Analyst Day announcement (2026) (opens in a new tab)
- Definium Therapeutics Investor and Analyst Day presentation (2026) (opens in a new tab)
- Definium Therapeutics January 2026 corporate presentation (2026) (opens in a new tab)
- Definium Therapeutics LSD fact sheet (2026) (opens in a new tab)
- Definium Therapeutics May 2026 corporate presentation (2026) (opens in a new tab)
- Definium Therapeutics MDD Breakthrough Therapy designation announcement (2026) (opens in a new tab)
- Definium Therapeutics NEI Fall Congress announcement (2026) (opens in a new tab)
- Definium Therapeutics Panorama topline presentation (2026) (opens in a new tab)
- Definium Therapeutics Panorama topline results announcement (2026) (opens in a new tab)
- Definium Therapeutics rebrand announcement (2026) (opens in a new tab)
- Definium Therapeutics second quarter 2026 results announcement (2026) (opens in a new tab)
- Definium Therapeutics third quarter 2026 earnings call transcript (2026) (opens in a new tab)
- Definium Therapeutics third quarter 2026 results announcement (2026) (opens in a new tab)
- Definium Therapeutics third quarter Form 10-Q (2026) (opens in a new tab)
- Definium Therapeutics ticker change announcement (2026) (opens in a new tab)
- Definium Therapeutics Voyage topline presentation (2026) (opens in a new tab)
- Definium Therapeutics Voyage topline results announcement (2026) (opens in a new tab)
- Definium Therapeutics Wired for Worry announcement (2026) (opens in a new tab)
- DeGeorge et al. (2022) (opens in a new tab)
- Dieleman et al. (2020) (opens in a new tab)
- Dolder et al. (2017) (opens in a new tab)
- Domschke et al. (2024) (opens in a new tab)
- Duong et al. (2024a) (opens in a new tab)
- Duong et al. (2024b) (opens in a new tab)
- Duong et al. (2024c) (opens in a new tab)
- Duong et al. (2024d) (opens in a new tab)
- Duong et al. (2024e) (opens in a new tab)
- Duong et al. (2026) (opens in a new tab)
- eCFR 21 CFR 1308.11 (opens in a new tab)
- Effexor XR prescribing information (2023) (opens in a new tab)
- EMA Lyrica product information (2026) (opens in a new tab)
- Etkin et al. (2009) (opens in a new tab)
- Ettman et al. (2025) (opens in a new tab)
- Executive Office of the President (2026) (opens in a new tab)
- FDA benzodiazepine boxed warning (2020) (opens in a new tab)
- FDA psychedelic drugs clinical investigations guidance (2026) (opens in a new tab)
- Ferries et al. (2025) (opens in a new tab)
- Ferries et al. (2026) (opens in a new tab)
- Fonzo and Etkin (2017) (opens in a new tab)
- Frokjaer et al. (2008) (opens in a new tab)
- Gasser et al. (2014) (opens in a new tab)
- Gasser et al. (2015) (opens in a new tab)
- Generoso et al. (2017) (opens in a new tab)
- Gomez et al. (2018) (opens in a new tab)
- Gonçalves and Byrne (2012) (opens in a new tab)
- Goodwin et al. (2020) (opens in a new tab)
- Grant et al. (2005) (opens in a new tab)
- Grant et al. (2009) (opens in a new tab)
- Greenberg et al. (1999) (opens in a new tab)
- Guaiana et al. (2010) (opens in a new tab)
- Hamilton (1959) (opens in a new tab)
- Harrewijn et al. (2021) (opens in a new tab)
- Healthmonix 2026 Mental and Behavioral Health Registry announcement (2026) (opens in a new tab)
- Hettema et al. (2001) (opens in a new tab)
- Hidalgo et al. (2007) (opens in a new tab)
- Hoffman et al. (2008) (opens in a new tab)
- Holze et al. (2019) (opens in a new tab)
- Holze et al. (2021) (opens in a new tab)
- Holze et al. (2022a) (opens in a new tab)
- Holze et al. (2022b) (opens in a new tab)
- Holze et al. (2023) (opens in a new tab)
- Holze et al. (2024a) (opens in a new tab)
- Holze et al. (2024b) (opens in a new tab)
- HRA Phase 1 PK study of MM-120 in healthy volunteers (2023) (opens in a new tab)
- HRA Phase 1 PK study of MM-120 under fed and fasted conditions (2024) (opens in a new tab)
- ICER esketamine final evidence report (2019) (opens in a new tab)
- ISRCTN ISRCTN11052603 (opens in a new tab)
- ISRCTN ISRCTN15997848 (opens in a new tab)
- Jacobsen et al. (2026) (opens in a new tab)
- Janssen SPRAVATO prescribing information (2025) (opens in a new tab)
- Kanwar et al. (2013) (opens in a new tab)
- Katzman et al. (2014) (opens in a new tab)
- Kessler et al. (2005a) (opens in a new tab)
- Kessler et al. (2005b) (opens in a new tab)
- Kessler et al. (2008) (opens in a new tab)
- Kessler et al. (2012) (opens in a new tab)
- Konnopka and König (2020) (opens in a new tab)
- Kroenke et al. (2007) (opens in a new tab)
- Levey et al. (2020) (opens in a new tab)
- Lexapro prescribing information (2024) (opens in a new tab)
- Louie (2026) (opens in a new tab)
- Luethi et al. (2019) (opens in a new tab)
- Lyrica prescribing information (2025) (opens in a new tab)
- Malberg et al. (2026) (opens in a new tab)
- Maneeton et al. (2016) (opens in a new tab)
- Martens et al. (2010) (opens in a new tab)
- Mavranezouli et al. (2013) (opens in a new tab)
- Meier et al. (2016) (opens in a new tab)
- MindMed APA presentation announcement (2024) (opens in a new tab)
- MindMed Breakthrough Therapy designation announcement (2024) (opens in a new tab)
- MindMed Catalent license announcement (2023) (opens in a new tab)
- MindMed corporate presentation (2025) (opens in a new tab)
- MindMed end-of-phase 2 meeting announcement (2024) (opens in a new tab)
- MindMed full-year 2024 results announcement (2025) (opens in a new tab)
- MindMed IND clearance announcement (2022) (opens in a new tab)
- MindMed IND clinical hold announcement (2021) (opens in a new tab)
- MindMed Innovation Passport announcement (2024) (opens in a new tab)
- MindMed JAMA publication announcement (2025) (opens in a new tab)
- MindMed Liechti and Holze anxiety trial announcement (2022) (opens in a new tab)
- MindMed MMED008 protocol (2023) (opens in a new tab)
- MindMed MMED008 statistical analysis plan (2023) (opens in a new tab)
- MindMed ODT patent announcement (2024) (opens in a new tab)
- MindMed Panorama first patient dosed announcement (2025) (opens in a new tab)
- MindMed Phase 2b and ODT bridging presentation (2024) (opens in a new tab)
- MindMed Phase 2b enrollment completion announcement (2023) (opens in a new tab)
- MindMed Phase 2b first patient dosed announcement (2022) (opens in a new tab)
- MindMed Phase 2b topline results announcement (2023) (opens in a new tab)
- MindMed suicidal ideation study announcement (2025) (opens in a new tab)
- MindMed third quarter 2025 results announcement (2025) (opens in a new tab)
- MindMed Voyage first patient dosed announcement (2024) (opens in a new tab)
- Munir and Takov (2022) (opens in a new tab)
- Mustafa et al. (2024) (opens in a new tab)
- Muthukumaraswamy et al. (2021) (opens in a new tab)
- National Institute of Mental Health generalized anxiety disorder statistics (opens in a new tab)
- NCQA Use of High-Risk Medications in Older Adults measure description (opens in a new tab)
- Newman et al. (2013) (opens in a new tab)
- NICE clinical guideline CG113 (2011) (opens in a new tab)
- Olatunji et al. (2007) (opens in a new tab)
- Patriquin and Mathew (2017) (opens in a new tab)
- Paxil prescribing information (2026) (opens in a new tab)
- Penninx et al. (2021) (opens in a new tab)
- Plummer et al. (2016) (opens in a new tab)
- Powdar et al. (2025) (opens in a new tab)
- Purves et al. (2020) (opens in a new tab)
- Revicki et al. (2012) (opens in a new tab)
- Ringeisen et al. (2023) (opens in a new tab)
- Robison et al. (2025) (opens in a new tab)
- Robison et al. supplementary appendix (2025) (opens in a new tab)
- Roest et al. (2010) (opens in a new tab)
- Ross and Soeteman (2020) (opens in a new tab)
- Roy-Byrne et al. (2010) (opens in a new tab)
- RTI International (2023) (opens in a new tab)
- Rubio and Lopez-Ibor (2007) (opens in a new tab)
- Ruscio et al. (2017) (opens in a new tab)
- Seroquel XR prescribing information (2025) (opens in a new tab)
- Shirneshan et al. (2013) (opens in a new tab)
- Slee et al. (2019) (opens in a new tab)
- Soares (2025) (opens in a new tab)
- Solmi et al. (2022) (opens in a new tab)
- Spitzer et al. (2006) (opens in a new tab)
- Stein and Sareen (2015) (opens in a new tab)
- Straumann et al. (2023) (opens in a new tab)
- Strawn et al. (2018) (opens in a new tab)
- Strom et al. (2026) (opens in a new tab)
- Szuhany and Simon (2022) (opens in a new tab)
- Terlizzi and Villarroel (2020) (opens in a new tab)
- Terlizzi and Zablotsky (2024) (opens in a new tab)
- Thielking et al. (2026) (opens in a new tab)
- Tucker et al. (2018) (opens in a new tab)
- USPSTF anxiety screening recommendation (2023) (opens in a new tab)
- Vistaril prescribing information (2014) (opens in a new tab)
- Vizeli et al. (2021) (opens in a new tab)
- Xanax prescribing information (2023) (opens in a new tab)
- Yang et al. (2021) (opens in a new tab)
- Yonkers et al. (1996) (opens in a new tab)